The short answer
- Your rate depends far more on the type and stage than on the word cancer.
- The clock starts when treatment ends, not at diagnosis.
- Some cancers - early thyroid, basal and squamous skin - barely affect your rate.
- A decline is disclosable forever, so pre-screen before you formally apply.
The reassuring truth
Type and time decide your rate
Cancer underwriting is not one rule. An early thyroid cancer and a late-stage lung cancer are entirely different applications - and for most survivors, enough time makes cover very reachable.
Check my options →This page is the by-type reference. For how the waiting periods, flat extras and reapplying actually work, read it alongside our guide to life insurance after cancer, which covers the mechanics that apply to every type.
Typical waiting periods by cancer type
| Cancer type | Usual wait | What decides it |
|---|---|---|
| Basal / squamous cell skin | None | Often ignored entirely |
| Thyroid, papillary | 1 - 2 years | Usually favourable |
| Melanoma in situ (stage 0) | 1 year | Depth (Breslow) is everything |
| Breast, early stage | 1 - 3 years | Stage, grade, hormone and HER2 status |
| Prostate, low risk | 1 - 3 years | Gleason score and PSA trend |
| Cervical / bladder, early | 1 - 3 years | Stage and recurrence |
| Colon, stage 1 - 2 | 2 - 5 years | Nodes involved |
| Blood cancers | 5 years or more | Type; some indolent forms milder |
| Lung, or any stage 3+ | 5 years or more | Harder; longer waits |
| In active treatment | Postponed | Guaranteed issue only |
Breast cancer
The details that move a breast cancer application are stage, grade, and the hormone and HER2 receptor status, along with how long since treatment. Early stage disease with a good prognosis often reaches standard rates with a flat extra after one to three years. Ongoing hormone therapy such as tamoxifen is expected and does not count against you.
Prostate cancer
For prostate cancer, the Gleason score and your PSA trend are what underwriters read most closely. Low-risk disease treated successfully, with PSA staying down, is frequently insurable at a modest rating within a couple of years. Active surveillance without treatment is assessed on its own terms and is often viewed reasonably.
Melanoma
Melanoma is all about depth. A melanoma in situ or a thin lesion has a very different outlook from a thick or ulcerated one, and the Breslow measurement from your pathology report drives the decision. Thin, early melanoma often needs only a short wait; deeper disease needs years.
The pathology report is the whole case
Whatever your cancer, the single most useful thing before you apply is your pathology and treatment summary - stage, grade, nodal status, receptor or marker results, and the date treatment ended. Supplying it up front produces a faster, more accurate assessment, and often a better one, than leaving the underwriter to request records piecemeal.
The order to apply
- Get your pathology report and treatment dates together first
- Have an agent pre-screen you informally - carrier views on specific cancers diverge sharply
- Apply where your type is treated well, so no decline lands on your record
- Reapply as time passes - your rate improves with each clear year, so a policy bought early can be replaced cheaper later
Common questions
How long after breast cancer can you get life insurance?+
Often one to three years after treatment ends for early stage disease with a good prognosis, typically at standard rates with a flat extra. Stage, grade and receptor status all factor in, and ongoing hormone therapy such as tamoxifen does not count against you.
Does prostate cancer stop you getting life insurance?+
No. Low-risk prostate cancer treated successfully, with PSA staying down, is often insurable at a modest rating within a couple of years. The Gleason score and PSA trend matter most, and active surveillance is assessed on its own terms.
Can you get life insurance after melanoma?+
Yes, and depth is the deciding factor. A melanoma in situ or a thin early lesion often needs only a short wait, while deeper or ulcerated melanoma requires several years. Your Breslow measurement from the pathology report drives the outcome.
What about blood cancers like leukemia or lymphoma?+
These usually need a longer wait, often five years or more, but it varies enormously by exact type - some indolent lymphomas are viewed far more gently than aggressive leukemias. Carrier appetite differs sharply, so pre-screening matters.